Senhwa Biosciences Inc., of Taipei, Taiwan, said casein kinase 2 (CK2) is the right target to aim at when developing a COVID-19 therapeutic treatment. The company’s silmitasertib is the only clinical-stage inhibitor of CK2, a kinase recently identified by researchers as being hijacked by SARS-CoV-2.

With Glaxosmithkline plc (GSK) having sailed through an FDA advisory panel meeting July 14 centered on its belantamab mafodotin (belantamab), an antibody-drug conjugate (ADC) for multiple myeloma (MM), others in the B-cell maturation antigen (BCMA) space such as Legend Biotech Corp. are further piquing Wall Street’s interest.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Angion, Arch, Avelas, Cellectar, Clene, Karuna, Keros, GT, Novartis, Oncopeptides, Regenxbio.

Since more than 40% of U.S. coronavirus deaths have links to U.S. long-term care facilities, Eli Lilly and Co. is getting on the road with a clinical trial design that takes researchers directly to outbreaks.

Novartis AG didn’t say why the FDA has put off action until September – a delay of three months – on the sBLA for multiple sclerosis (MS) prospect Arzerra (ofatumumab, OMB-157), first cleared in October 2009 for chronic lymphocytic leukemia, but the holdup brought renewed attention to the bustling space, and Immunic Inc. – which held its R&D Day on May 27 – is coming on strong.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Akebia, Amgen, Active, Aileron, Arcutis, Biohaven, Cymabay, Genmab, Immunic, Innovent, Janssen, Kadimastem, Lilly, Lipocine, Myokardia, Polyphor, Takeda.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, American Brivision, Arch, Astrazeneca, Biontech, Bridgebio, Chiasma, Cleave, Corcept, Cue, Grifols, Interion, Mind, Miragen, Orion, Pfizer, Plus, Reata, Recordati, Redhill, Spectrum.